Companies / Viking Therapeutics Inc / Activity
Activity — Viking Therapeutics Inc
36 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Lian Brian CEO | Sell | Common Stock, par value $0.00001 per share | $4.28M | -132K -4.85% | 2,600,246 2.23% of shares | medium |
| Jan 5, 2026 | Lian Brian CEO | Sell | Common Stock, par value $0.00001 per share | $1.78M | -53K -2.05% | 2,546,967 2.18% of shares | medium |
| Jan 5, 2026 | Lian Brian CEO | Sell | Common Stock, par value $0.00001 per share | $1.41M | -41K -1.62% | 2,505,691 2.15% of shares | medium |
| Jan 5, 2026 | Zante Greg Executive | Sell | Common Stock, par value $0.00001 per share | $1.03M | -32K -12.91% | 215,571 0.18% of shares | medium |
| Jan 5, 2026 | Mancini Marianna Executive | Sell | Common Stock, par value $0.00001 per share | $1.03M | -32K -6.85% | 434,890 0.37% of shares | medium |
| Jan 2, 2026 | Foehr Matthew W Director | Sell | Common Stock, par value $0.00001 per share | $561.7K | -16K -10.81% | 132,036 0.11% of shares | medium |
| Jan 5, 2026 | Zante Greg Executive | Sell | Common Stock, par value $0.00001 per share | $464.0K | -14K -6.45% | 201,671 0.17% of shares | medium |
| Jan 5, 2026 | Mancini Marianna Executive | Sell | Common Stock, par value $0.00001 per share | $453.9K | -14K -3.13% | 421,290 0.36% of shares | medium |
| Jan 5, 2026 | Mancini Marianna Executive | Sell | Common Stock, par value $0.00001 per share | $359.3K | -11K -2.49% | 410,790 0.35% of shares | medium |
| Jan 5, 2026 | Zante Greg Executive | Sell | Common Stock, par value $0.00001 per share | $352.6K | -10K -5.11% | 191,371 0.16% of shares | medium |
| Jan 5, 2026 | Lian Brian CEO | Sell | Common Stock, par value $0.00001 per share | $224.4K | -6K -0.26% | 2,499,291 2.14% of shares | medium |
| Mar 10, 2026 | Aubuchon Neil William Executive | Buy | Common Stock, par value $0.00001 per share | $149.9K | +4K | 4,475 <0.01% of shares | medium |
| Jan 5, 2026 | Mancini Marianna Executive | Sell | Common Stock, par value $0.00001 per share | $56.1K | -2K -0.39% | 409,190 0.35% of shares | low |
| Jan 2, 2026 | Foehr Matthew W Director | Exercise | Common Stock, par value $0.00001 per share | $53.3K | +16K +12.12% | 148,036 0.13% of shares | low |
| Jan 5, 2026 | Zante Greg Executive | Sell | Common Stock, par value $0.00001 per share | $48.1K | -2K -0.78% | 189,891 0.16% of shares | low |
| Jan 2, 2026 | Mancini Marianna Executive | Grant | Common Stock, par value $0.00001 per share | $0 | +32K +7.37% | 466,851 0.40% of shares | low |
| Jan 2, 2026 | Mancini Marianna Executive | Grant | Common Stock, par value $0.00001 per share | $0 | +41K +10.41% | 434,802 0.37% of shares | low |
| Jan 2, 2026 | Rouan Sarah Kathryn Director | Grant | Common Stock, par value $0.00001 per share | $0 | +3K +254.03% | 4,390 <0.01% of shares | low |
| Jan 2, 2026 | Lian Brian CEO | Grant | Common Stock, par value $0.00001 per share | $0 | +224K +8.93% | 2,732,700 2.34% of shares | low |
| Jan 2, 2026 | Lian Brian CEO | Grant | Common Stock, par value $0.00001 per share | $0 | +78K +3.23% | 2,508,620 2.15% of shares | low |
| Jan 2, 2026 | Zante Greg Executive | Grant | Common Stock, par value $0.00001 per share | $0 | +32K +14.87% | 247,532 0.21% of shares | low |
| Jan 2, 2026 | Zante Greg Executive | Grant | Common Stock, par value $0.00001 per share | $0 | +41K +23.50% | 215,483 0.18% of shares | low |
| Jan 2, 2026 | Singleton J Matthew Director | Grant | Common Stock, par value $0.00001 per share | $0 | +3K +33.16% | 12,650 0.01% of shares | low |
| Jan 2, 2026 | Macartney Lawson Director | Grant | Common Stock, par value $0.00001 per share | $0 | +3K +6.57% | 51,115 0.04% of shares | low |
| Jan 2, 2026 | Rowland Charles A Jr Director | Grant | Common Stock, par value $0.00001 per share | $0 | +3K +10.50% | 33,150 0.03% of shares | low |
| Jan 2, 2026 | Foehr Matthew W Director | Grant | Common Stock, par value $0.00001 per share | $0 | +3K +2.39% | 135,186 0.12% of shares | low |
| Jan 2, 2026 | Mancini Marianna Executive | Grant | Stock Option (Right to Buy) | — | +91K | 91,000 0.08% of shares | low |
| Jan 2, 2026 | Rouan Sarah Kathryn Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,400 0.02% of shares | low |
| Jan 2, 2026 | Lian Brian CEO | Grant | Stock Option (Right to Buy) | — | +176K | 176,300 0.15% of shares | low |
| Jan 12, 2026 | Aubuchon Neil William Executive | Grant | Stock Option (Right to Buy) | — | +180K | 180,000 0.15% of shares | low |
| Jan 2, 2026 | Zante Greg Executive | Grant | Stock Option (Right to Buy) | — | +91K | 91,000 0.08% of shares | low |
| Jan 2, 2026 | Singleton J Matthew Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,400 0.02% of shares | low |
| Jan 2, 2026 | Macartney Lawson Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,400 0.02% of shares | low |
| Jan 2, 2026 | Rowland Charles A Jr Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,400 0.02% of shares | low |
| Jan 2, 2026 | Foehr Matthew W Director | Grant | Stock Option (Right to Buy) | — | +20K | 20,400 0.02% of shares | low |
| Jan 2, 2026 | Foehr Matthew W Director | Exercise | Stock Option (Right to Buy) | — | -16K -100.00% | 0 0.00% of shares | low |